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Live herpesvirus-vectored vaccines are widely used in veterinary medicine to protect against many infectious diseases. In poultry,
three strains of herpesvirus vaccines are used against Marek’s disease (MD). However, of these, only the herpesvirus of turkeys (HVT)
has been successfully developed and used as a recombinant vaccine vector to induce protection against other avian viral diseases
such as infectious bursal disease (IBD), Newcastle disease (ND) or avian influenza (AI). Although effective when administered
individually, recombinant HVT vectors have limitations when combined in multivalent vaccines. Thus there is a need for developing
additional viral vectors that could be combined with HVT in inducing protection against multiple avian diseases in multivalent
vaccines. Gallid herpesvirus 3 (GaHV3) strain SB-1 is widely used by the poultry industry as bivalent vaccine in combination with HVT
to exploit synergistic effects against MD. Here, we report the development and application of SB-1 as a vaccine vector to express
the VP2 capsid antigen of IBD virus. A VP2 expression cassette was introduced into the SB-1 genome at three intergenic locations
(UL3/UL4, UL10/UL11 and UL21/UL22) using recombineering methods on the full-length pSB-1 infectious clone of the virus. We
show that the recombinant SB-1 vectors expressing VP2 induced neutralising antibody responses at levels comparable to that of
commercial HVT-based VAXXITEKHVT+IBD vaccine. Birds vaccinated with the experimental recombinant SB-1 vaccine were protected
against clinical disease after challenge with the very virulent UK661 IBDV isolate, demonstrating its value as an efficient viral vector
for developing multivalent vaccines against avian diseases.
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INTRODUCTION
Marek’s disease virus (MDV-1) or Gallid herpesvirus 2, belonging to
the Mardivirus genus in the family Herpesviridae, is the causative
agent of Marek’s disease (MD) characterised by rapid-onset
lymphomatous tumours and paralytic symptoms due to neuronal
infiltration of lymphocytes. In infected birds, MDV replicates in the
feather follicle epithelial cells, from where it is transmitted to other
birds by inhalation of infected dust and dander. The mortality rate
from MD usually varies between 10–30%, but can be up to 100%
dependent on infecting strain, host susceptibility and/or vaccina-
tion status. MD has been controlled for more than 4 decades by
the widespread use of live attenuated vaccines.1,2 Vaccine strains
include the naturally attenuated MDV-1 strain Rispens (CVI988),
MDV-2 (GaHV3) strain SB-1 and herpesvirus of turkeys (HVT) strain
FC126.
In addition to their use as successful vaccines inducing long-
term protection against MD, avian herpesvirus vaccine strains also
have the potential to be used as recombinant vaccine viral vectors
for inducing protection against other major avian diseases. The
most successful and widely-used recombinant herpesvirus vaccine
vector is the HVT strain which has been shown to be highly
effective in protecting against a number of avian viral patho-
gens,3–6 even in the presence of maternal antibodies.7 Although
individual recombinant HVT vaccines have proven to be extremely
effective, combined use of more than one recombinant HVT
vaccine has been shown to be less so. This is thought to be due to
the interference between different HVT vaccines, because of
which manufacturers do not recommend the use of combinations
of HVT-based vaccines.8 Thus the combined use of HVT to protect
against MD and another recombinant HVT vectored vaccine to
induce protection against a second disease, may lead to a failure.
Generation of multivalent HVT vectors expressing multiple foreign
genes have also been technically challenging. With these
constraints on the use of HVT vectored vaccines, there is a need
for developing other vector platforms that will not interfere, but
rather complement the induction of protective responses against
multiple antigens in the vaccine.
The first GaHV3 strain that was licensed for use as a vaccine
against MD was the SB-1 strain.9 It was originally introduced in the
mid-1980s and is still used very successfully in combination with
the HVT vaccine, inducing protection against very virulent MDV
pathotypes.2 Commercial bivalent vaccines containing SB-1 and
HVT FC126 strains are widely used in many countries including
USA, South America and Asia.1,10 SB-1/HVT bivalent vaccines are
thought to provide superior protection against MD through a
complementing effect2,11 even in maternal antibody-positive
chicks.11 Because of the complementing effects of the HVT and
SB-1 strains in inducing protection against MD, we reasoned that
the SB-1 recombinant viral vector could be used as a bivalent
vaccine in combination with recombinant HVT with complemen-
tary rather than inhibitory effects. We have previously shown that
recombinant HVT expressing HA of AI virus was capable of
producing immunity against MDV and AI lethal challenge.4
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The 166-Kb genome of the SB-1 strain of GaHV3 has a similar
genome organisation as MDV-1, sharing a number of homologous
genes12 as well as unique set of genes and microRNAs.13 We have
previously reported the construction of the full-length infectious
genome of the SB-1 strain in a bacterial artificial chromosome
(BAC) that could be used as a reverse genetics tool for
manipulation of the viral genome.14,15 We have also shown that
the virus reconstituted from the recombinant SB-1 BAC clone
induced strong protection against virulent MDV challenge.15 This
has allowed us to develop SB-1 as a recombinant vector for
expressing protective antigens from other avian pathogens using
the well-established recombineering techniques.16 Here we report
the construction of a recombinant SB-1 viral vector engineered to
express the VP2 capsid protein17 of infectious bursal disease virus
(IBDV) to induce immune responses and protection against the
very virulent UK661 IBDV isolate.
RESULTS
Generation of SB-1-UL3/4VP2, SB-1-UL10/11VP2 and SB-1-UL21/
22VP2 viruses
The expression for IBDV VP2 was derived from a murine
cytomegalovirus immediate early protein 2 (mCMV IE2) promoter
and the VP2 gene was derived from IBDV strain Faragher 52/70
with a SV40 early polyadenylation signal (Venugopal Nair,
unpublished data). Expression of VP2 in cells infected with
recombinant SB-1 viruses was assessed by staining with the
anti-IBDV VP2 mouse monoclonal antibodies clone HH7 (IgG1)
(Fig. 1 Panels A to D). SB-1 infection was confirmed by staining
with anti-gB antibody Y5.9 (IgG1)18 (Fig. 1, Panels E to H). Virus
plaques were visualised by antibody staining followed by colour
development using peroxidase (HRP) substrate (Fig. 1i for pSB-1,
Fig. 1j for pSB-1-UL3/4VP2, Fig. 1k for pSB-1-UL21/22VP2 and Fig.
1l for pSB-1-UL10/11VP2). Recombinant SB-1 virus isolated from
cells that had been transfected with the BAC DNA was passaged
three times in primary chicken embryonic fibroblast (CEF) cells to
produce virus stocks. Studies comparing the in vitro growth
showed no significant differences between the parental pSB-1
virus and the recombinant SB-1-UL3/4VP2 viruses between 12 and
48 h post-infection (Fig. 2). All of the recombinant SB1 viruses
showed reduced levels of replication at time points 72, 96 and
120 h post infection. Based on a two way ANOVA with multiple
comparisons test, there is a significant difference between SB1
and SB-1-UL3/4VP2 growth rate at time points 72 and 120 h (p=
0.0031 and p= 0.0001, respectively). Likewise, at time points 72
and 120 h post infection, a significant difference was observed
between pSB-1 and SB-1-UL21/22VP2 (p= 0.0094 and p= 0.0001,
respectively). In comparison with the other two recombinant
viruses, SB-1-UL3/4VP2 showed a significant difference at time
points 72, 96 and 120 h post infection (p= 0.0194, p= 0.0284 and
p= 0.0001, respectively). Overall, the replication rate for all three
viruses were slower compared to the parental virus.
Immune response to vaccination and protection against virulent
infection
Considering that IBDV strain UK661 does not grow efficiently in
DF-1 cells, we used the IBDV vaccine strain D78 to perform
neutralisation assays. Usage of IBDV strain D78 gave us the
opportunity to detect viral cytopathic effect on the adherent DF-1
cell line. The amino acid sequence of the VP2 gene from strain
UK661 has 99% identity with strain F52/70 and 98% identity with
strain D78. (GenBank accession numbers EU162087.1,
NC_004178.1 and D00869.2).19–21
Fig. 1 a–d Infected cells stained against SB-1 with anti gB Y5.9 antibody (IgG1) followed by Alexa Fluor 568 staining. e–h infected cells stained
separately against IBDV VP2 with anti VP2 antibody HH7 (IgG1) followed by Alexa Flour 488 staining. The nuclei of the cells are stained with
DAPI and shown in blue (scale bar= 30 µm). a and e show CEF cells infected with parental pSB-1 virus, b and f show CEF cells infected with
pSB-1-UL3/4VP2 recombinant virus, c and g show CEF cells infected with pSB-1-UL10/11VP2 recombinant virus and d and h show CEF cells
infected with pSB-1-UL21/22VP2 recombinant virus. i–l show plaque formation in CEF cells infected with pSB-1 (i), CEF cells infected with pSB-
1-UL3/4VP2 (j), pSB-1-UL21/22VP2 (l) and pSB-1-UL10/11VP2 (k) recombinant viruses (scale bar= 200 µm)
Gallid herpesvirus 3 SB-1 strain as a recombinant viral vector
Y Sadigh et al.
2
npj Vaccines (2018)  21 Published in partnership with the Sealy Center for Vaccine Development
1
2
3
4
5
6
7
8
9
0
()
:,;
As it is shown in Fig. 3a, neutralising antibodies were detectable
from week two onwards in all of the groups except for birds
vaccinated with the SB-1-UL21/22VP2 vaccine. However, neutralis-
ing antibodies against IBDV were detected in the sera of all the
birds in the four groups at 4 weeks post-vaccination (Fig. 3a), with
no significant differences between the groups in the mean
antibody levels.
Further evaluation of the recombinant SB-1 vaccine to induce
protection against IBD was carried out in Experiment 2 using an
IBDV challenge model by infecting with very virulent UK661 strain
at 4 weeks post-vaccination. Pre-challenge serum samples
collected 3-weeks after vaccination and analysed for the presence
of neutralising antibodies. The results are shown in Fig. 3b. It was
shown that in groups VAXXITEKHVT+IBD and SB-1-UL3/4VP2 one
bird in each group and three birds in SB-1-UL21/22VP2 group had
neutralising antibodies (Fig. 3b). Infection by intranasal adminis-
tration of 104.3 TCID50 of IBDV strain UK661 induced clinical signs
only in birds inoculated with the control pSB-1 virus lacking VP2.
The mean clinical scores of the disease in the different groups of
birds during the post-challenge period are shown in Fig. 4. Clinical
signs seen in the pSB-1 control group appeared from about 36 h
post challenge and increased sharply until 56 h post challenge
(Fig. 4a). At this time, the last remaining bird was euthanized
before reaching the humane end point. All of the vaccinated birds
survived (Fig. 4b), demonstrating clinical protection against the
disease (p < 0.0001).
Gene expression analysis. A SYBR green real-time PCR based assay
was designed to study the level of expression of viral genes adjacent
to the VP2 expression cassette. According to our data, in SB-1-UL21/
22VP2, the expression level of UL21 was increased by about 4 folds;
whereas the expression level of UL22 dropped by 2 folds (Fig. 5a). In
cells infected with the SB-1-UL10/11VP2 virus, the level for both
UL10 and UL11 transcripts were modestly increased (Fig. 5b). Finally,
in cells infected with SB-1-UL3/4VP2 infected cells (Fig. 5c), level of
UL3 and UL4 transcripts were dropped by about 4 folds.
In addition to the expression level for the genes adjacent to the
VP2 cassette, we have calculated the level of expression for VP2 in
the cells infected with the three vaccine vectors (Fig. 5d). Figure
5d shows, ΔCt value for expression level of VP2 normalised to the
level of GAPDH. According to the results, more VP2 was expressed
in CEF cells that were infected with SB-1-UL3/4VP2 compared to
SB-1-UL21/22VP2 (p= 0.0298) or SB-1-UL10/11VP2 (p= 0.0035).
DISCUSSION
Avian herpesvirus vaccines used against poultry diseases such as
MD offer the additional advantage of being developed as
potential viral vectors for inducing simultaneous protection
against other avian diseases. The best example of this is the
commercial use of recombinant HVT22,23 as a successful vaccine
inducing simultaneous protection against MD and IBD. While HVT
is a highly efficient recombinant vector that could be used to
induce strong immune response to a number of avian pathogens,
widespread usage of HVT-vectored vaccines is hampered by the
apparent interference between the recombinant viruses, for
Fig. 3 a Experiment 1—Titre of neutralising antibodies in the sera of
chickens vaccinated with VAXXITEKHVT+IBD ( ), SB-1-UL3/4VP2 ( ),
SB-1-UL21/22VP2 ( ) or SB-1-UL10/11VP2 ( ) vaccine viruses.
Serum samples were collected at weeks 2, 3 and 4 post-
vaccination. The mean titre in each group is shown as a horizontal
bar. b Experiment 2—Titre of neutralising antibodies in week
3 serum of chickens vaccinated with VAXXITEKHVT+ IBD ( ), SB-1-
UL3/4VP2 ( ), SB-1-UL21/22VP2 ( ) or SB-1-UL10/11VP2 ( ).
Individual values are shown. Group names are given on the X-axis
Fig. 2 Growth curve for SB-1 recombinant viruses in vitro. Time
course experiment was performed in triplicate with each time point
was infected independently. Each replicate was titrated in duplicate.
PFU in 1ml of infected cell suspension was calculated for each time
point; SB-1( ), SB-1-UL3/4VP2 ( ), SB-1-UL10/11VP2 ( ) and SB-1-
UL21/22VP2 ( ). A significant difference at time points 72 and 120 h
(p= 0.0031 and p= 0.0001, respectively) was observed for SB-1-UL3/
4VP2 when compared to its parental virus. Similarly, a significant
difference was observed between the titre of SB-1 and SB-1-UL21/
22VP2 time points 72 and 120 h (p= 0.0094 and p= 0.0001,
respectively). In comparison with the other two recombinant
viruses, SB-1-UL10/11VP2 showed a significant difference at time
points 72, 96 and 120 h post infection (p= 0.0194, p= 0.0284 and p
= 0.0001, respectively)
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reasons that remain poorly understood. Recombinant vaccines
based on other avian herpesvirus vaccine strains such as MDV-1
have been experimentally shown to be effective against diseases
such as IBD, but are not yet commercially available.24,25
Considering the need for protecting poultry against multiple
pathogens, there is the need for additional vector platforms that
can deliver protective antigens without interference with the
herpesvirus vaccines used in poultry.
In this study, we report the use of MDV-2 (GaHV3) strain SB-1 as
a viral vector, generating three independent constructs that
express IBDV VP2 in one of three different locations in the viral
genome: loci UL3/4, UL10/11 and UL21/22. The expression of the
VP2 cassette from the three loci appeared to slow the growth of
SB-1 in vitro. Among the three locations, the VP2 expressing
transcripts were appeared to have a higher level of expression
from the UL3-UL4 location compared to UL21-UL22 or UL10-UL11
loci. On the other hand, level of expression for the adjacent genes
was shown to be least affected when the transgene was expressed
from the UL10-UL11 location.
Immunogenicity of the recombinant SB-1 vaccines was assessed
by measuring the neutralising antibody levels in vaccinated
chickens. Neutralising antibodies started to appear from week 2
and rose to a maximum titre of 640 in week four post-vaccination.
All the birds in all four groups showed neutralising antibodies by
4 weeks. Although not statistically significant, the mean values of
neutralising antibodies in the groups inoculated with the
experimental vaccines were higher than those of the group that
received the commercial vaccine. In the second experiment, we
examined the effect of the SB-1 vaccines administered at a
reduced dose of 1000 plaque forming units (pfu), compared to the
3000–5000 pfu dose of VAXXITEKHVT+IBD given in both experi-
ments. In comparison with experiment 1, only a very limited
number of birds showed neutralising antibodies at week 3 post
vaccination, presumably reflecting the smaller dose given. In spite
of this, all of the groups showed 100% protection against IBDV
after an experimental challenge with the very virulent
UK661 strain of IBD virus, compared to the group vaccinated
with the parental pSB-1 vaccine that not express the VP2 antigen.
This suggests that the mechanism of protection may not be solely
mediated by high titres of serum neutralising antibodies, and that
cellular or mucosal responses may also contribute. However an
evaluation of the mechanism of protection is beyond the scope of
this study. Moreover, demonstration of protective responses
elicited by the recombinant SB-1 vaccine against very virulent
IBDV infection when used at levels comparable to the widely used
VAXXITEKHVT+IBD vaccine confirms the value of SB-1 as a
recombinant vaccine vector platform for avian diseases.
MDV and IBDV are highly infectious viruses producing diseases
with high mortality rates that have made them a constant threat
to the productivity of the worldwide poultry industry for decades.
The presence of maternal antibodies, emergence of new antigenic
and pathogenic variants, cost of production, and in some cases
lack of compliance with DIVA strategy (reviewed in26) are
challenges that limit the efficient control of IBDV, while MDV
vaccines have been demonstrated to drive virulence of the
pathogen over the last 50 years.26 Bivalent MDV/IBDV vaccines
allow for vaccination against both diseases simultaneously,
lowering the costs of production and inoculation. They are also
safer and can be given as in ovo vaccination, unlike attenuated
IBDV vaccines that cause subclinical IBD in chicks and are fatal to
embryos. While the VAXXITEKHVT+IBD vaccine based on the HVT
vector is widely used as a successful vaccine against IBD in many
countries, there is constraint on the use of this recombinant
vaccine in combination with other HVT-based vaccines, because of
interference with the induction of immune responses against the
components of other vaccines. Although the mechanisms of such
interference between HVT-based vaccines still remain unclear,
there is a definite need for other vector platforms that can
complement the HVT-based vectors in multivalent vaccines.
In this paper we show that a GaHV3 (MDV-2) strain SB-1, already
in use as a licensed vaccine against MD since the mid-1980s, can
be used as a viral vector expressing the IBDV VP2 capsid antigen
to induce complete protection against a challenge with a 100%
lethal dose of IBDV. We have identified three locations in the SB-1
genome that tolerated the VP2 expression cassette, and we
predict that these loci will also support the delivery of genes from
other pathogens as well. With a long history of successful use with
HVT as bivalent vaccine against MD, SB-1 has not shown any
interference in inducing immune responses against MD. On the
contrary, SB-1/HVT bivalent vaccines do provide superior protec-
tion against MD than either vaccine used alone, through
synergistic effects.2,27 Our results demonstrating the potential of
the recombinant SB-1 to protect against IBD offers immense
opportunities for its use as a bivalent vaccine together with
recombinant HVT to induce simultaneous protection against
multiple avian diseases, exploiting their enhanced synergistic
immune functions.
Fig. 4 a Clinical score in birds vaccinated with VAXXITEKHVT+IBD, SB-1-UL3/4VP2, SB-1-UL21/22VP2 and SB-1 following infection with10
4.3
TCID50 of IBDV strain UK661. Clinical scores are shown for individual birds. A rapid increase in the clinical score after 45 h post challenge was
observed in SB-1 group and increased to its highest level at 55 h post challenge when affected birds were euthanized for humane reasons. b
Percentage survival for the vaccinated birds challenged with IBDV UK661. Birds inoculated with pSB-1 were euthanized for humane reasons or
died 55 h post IBDV infection. VAXXITEKHVT+IBD ( ), SB-1( ), SB-1-UL3/4VP2 ( ), SB-1-UL21/22VP2 ( )
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MATERIALS AND METHODS
Cloning of IBDV VP2 expressing cassette into SB-1 virus genome
We have used the pSB-1 BAC clone14 to generate three different
recombinant viruses pSB-1-UL3/4VP2, pSB-1-UL10/11VP2 and pSB-1-
UL21/22VP2 that express the IBDV VP2 expression cassette in the UL3/4,
UL10/11 and UL21/22 intragenic loci of the SB-1 virus genome. The
location of insertion sites are given in Table 1. Methods for the galK
selection-based recombineering approach have been previously
described.16,28 Briefly, a galK expression cassette was inserted into the
three locations and positive colonies were selected based on their ability
to utilise galactose as the sole carbon source in a minimal media. The galK
cassette was then replaced by the VP2 expression cassette amplified from
the recombinant HVT expressing IBDV VP2.5 Positive colonies were
selected based on their ability to grow in the presence of 2-deoxy-
galactose28 and the integration of VP2 cassette was confirmed by specific
PCR and sequencing.
Cell culture and virus propagation
Chicken embryonic fibroblasts (CEF) were prepared from 9–10 day old
embryos of specific-pathogen-free (SPF) Rhode Island Red (RIR) birds in
E199 media (Sigma) with 5% foetal bovine serum. DF-1 cells were
propagated in Dulbecco’s modified Eagles medium (DMEM, Sigma) with
10% serum. DT40 cells were propagated in RPMI-1640 medium with 10%
serum. All of the cell culture media were supplemented with 100 U/ml
penicillin, 100 μg/ml streptomycin and 0.25 μg/ml fungizone.
For the preparation of recombinant virus stocks, CEF were transfected
with the BAC DNA from the recombinant constructs using Lipofectamine®
transfection reagent (ThermoFisher) and reconstituted viruses were
passaged to generate working virus stocks. Titration of SB-1 vaccine
viruses was performed in CEF and the titres calculated by counting the
plaque numbers four days post-infection. Recombinant virus plaques were
confirmed using immunostaining with IBDV VP2-specific mouse mono-
clonal antibody clone HH7 (IgG1)29 followed by staining with goat anti-
mouse HRP conjugated antibody (DAKO) and TrueBlue™ (KPL) peroxidase
substrate. Furthermore, CEF infected cells were stained with monoclonal
antibodies IA7 (anti-IBDV VP2) (IgG2a) (unpublished) and SB-1-specific
monoclonal antibody Y5.9.18 IA7 and SB-1 stained infected cells were
visualised with anti IgG2a Alexa Fluor 568 and anti IgG1 Alexa Fluor 488
antibodies, respectively. Stained cells examined with a Leica SP5 confocal
microscope.
Virulent IBDV UK661 strain was used as bursal tissue lysates from
infected birds harvested at 3 days post infection,30 and the D78 strain was
propagated in DF-1 cells and stored at −80 °C until use. Titrations of UK661
and D78 virus strains were performed in DT40 and DF-1 cells respectively
by calculating the median tissue culture infectious dose (TCID50) using the
Spearman-Karber method.31 IBDV strain D78 was used to perform virus
neutralisation test using DF-1 cells.
Fig. 5 Gene expression analysis for a UL21 and UL22 in cells infected with SB-1-UL21/22VP2, b UL10 and UL11 in cells infected with SB-1-
UL10/11VP2, and c UL3 and UL4 in cells infected with SB-1-UL3/4VP2 (c). Fold change expression was presented as 2−ΔΔCt on the Y-axis of
each graph. Expression of VP2 from the 3 insertion loci are shown (d) data are presented as ΔCt on the Y-axis. The groups are shown on the X
axis. A significant difference in the expression of VP2 was observed in cells which were infected with SB-1-UL3/4VP2 compared to the cells
infected with SB-1-UL21/22VP2 or SB-1-UL10/11VP2 (p= 0.0298 or p= 0.0035, respectively)
Table 1. Insertion locations for the VP2 expression cassette in SB-1
genome
Location Insertion site
UL3/4 GATCGAC19265- T19266CGCTTTC
UL10/11 CTAAATCT32130-A32131CAAGTG
UL21/22 GTATGTG49807-C9808CTCTACAG
Numbers correspond to the genomic location of Gallid herpes virus—3 (SB-
1) genome (GenBank accession number AB049735.1)
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Virus growth curve studies
Confluent CEF in 10 cm2 dishes were infected in duplicate with 100 μl of
103 pfu of SB-1 viruses. Following the infection, infected CEF cells were
harvested at time points 0, 12, 24, 48, 96 and 120 h post infection. The
harvested cells were titrated immediately by plaque assay. The experiment
was repeated independently three times.15,32,33
Validating the immunogenicity of vaccine viruses
One-day-old SPF RIR chicks reared at the Experimental Animal House at
Pirbright Institute were used for the validation experiments. All procedures
were performed in accordance with the UK Animal (Scientific Procedures) Act
1986 under Home Office Personal and Project licences, after the approval of
Animal Welfare Ethical Review Board (AWERB) at The Pirbright Institute.
Experiment 1. Forty 1-day old chicks were divided into 4 groups of 10
birds. Each of the three groups received subcutaneous injections of pSB-1
UL10/11 VP2, pSB-1 UL21/22 VP2 or pSB-1 UL3/4 VP2 vaccine viruses, each
comprising 3 × 103 pfu in 100 µl of inoculum. Each of the 10 birds in the
control group were vaccinated with 5 × 103 pfu of the VaxxitekHVT+IBD®
vaccine (Merial) as recommended by the manufacturer. Blood samples
were collected weekly from the second to the fifth week post vaccination
for serological studies.
Experiment 2. Two groups (8 birds per group) of 1-day old birds were
inoculated subcutaneously with 1000 pfu of pSB-1 UL3/4 VP2 or pSB-1
UL21/22 VP2 virus stocks. Two control groups were inoculated with either
pSB-1-derived parental virus (1000 pfu) or the commercial VaxxitekHVT+IBD®
vaccine respectively. After collecting the blood samples at four week post-
vaccination, birds were challenged intra-nasally with 104.3 TCID50 of the
virulent UK661 strain of IBDV (in a total volume of 100 µl divided between
the two nostrils). In addition to the recording of the body weight, clinical
score of birds were monitored regularly using a scoring system based on
appearance, behaviour, provoked behaviour and handling (supporting
materials 1). Clinical signs scored at 6-hourly intervals. Birds showing
advanced clinical signs (exceeding a score of 9) or if they scored 5 for two
consecutive intervals were euthanized by cervical dislocation.
Serology
Serum samples collected by centrifugation were heat treated at 56 °C for
30min to inactivate complement factors, prior to the neutralisation test.
Briefly, serial dilutions of sera samples were incubated with 100 TCID50 of
D78 strain of IBDV for one hour at 37 °C, and the serum-virus mixtures were
incubated with DF-1 monolayer in 96 well plates for one hour, before
replacing with 2% DMEM media. The cells were checked after four days for
evidence of cytopathic effects to determine serum neutralisation titres. The
highest dilution of the serum that prevented cytopathic effect was
considered as the neutralisation titre.
Real-time PCR assay for analysis of gene expression
Confluent CEF cells were infected with 500 pfu of SB-1 viruses in 3.45 cm
diameter tissue culture plates. Infected cells were harvested 72 h post
infection. The cells were washed with PBS and scraped from the plate. RNA
purification was performed using RNeasy Qiagen kit. Extracted RNA was
treated with DNAseI (New England Biolabs) for 30min followed by heat
inactivation at 75° to degrade any carry over DNA. Reverse transcription was
performed using random primers and Revertaid reverse transcriptase
(Thermo Fisher Scientific) as described by the manufacturer. SYBR green
based real-time PCR assay was performed using PowerUp SYBR green
master mix (Thermo Fisher Scientific). The real-time PCR reactions were
assembled in 10 μl volumes and in an Applied Biosystems 7500 fast real-
time-PCR system. PCR cycles were programmed as recommended by the
manufacturer with annealing at 60 °C (30 s) and extension at 72 °C (30 s).
The signal was collected at the extension cycle. Melt curve analysis was
performed after each PCR run to eliminate the possibility of non-specific
amplifications. To compare the data, ΔΔCt value was calculated for each
gene of interest. To do so, the Ct value of GAPDH in each real-time PCR
experiment was used as the house keeping gene. The Ct values for each of
the genes studied in CEF cells infected with SB-1 parental virus was used as
the calibrator. The assay was performed in three biological replicates with
all of the samples were kept at −20 and analysed at the same time for RNA
purification and Real-time PCR assay. SYBR green PCR primers were
designed using Primer3 primer design server. They were validated by
conventional PCR prior to perform the assay. PCR primers: GAPDH_-
SYBR_F1: actgtcaaggctgagaacgg, GAPDH_SYBR_R1: ctgcatccgcccatttgatg,
UL3_F: tctcgacgaattgggaagac, UL3_R: gagcttgaattaccgcttgc, UL4_F:
tcttatcggatcgcagctct, UL4_R:tggatgggaacgtcactgta, UL10_F:ggcat-
gattgttcgcctaat, UL10_R:tctcgtcgtctgatgtttcg, UL11_F:ccgaccgtccttaaatctga,
UL11_R:aacgaaacaccgttctgacc, UL21_F:gaggggcaacttaaacacca, UL21_R:
caattcccgcaactccttta, UL22_F:ccgcaatacggacattcttt, UL22_R:aatgttcgggcact-
gatagg, VP2_F: cttccaaggaagcctgagtg and VP2_R: tgtcactgctgtcgcatgta.
Statistical analysis
Two way ANOVA with multiple comparisons test was employed to
compare virus titres at each time point of the growth curve. Differences in
levels of neutralising antibody during the course of study and between the
groups were analysed using two-way ANOVA test. The level of antibodies
within each group was analysed using one-way ANOVA test. The survival
rate between groups of the birds after the challenge was compared using
the Mantel-Cox test.
ACKNOWLEDGEMENTS
We gratefully acknowledge valuable contribution of our colleagues whose help
sustained our progress towards completion of this work. Especially we would like to
thank Dr. Luca Ferretti and Dr. Paolo Ribeca for their advice on statistical analysis of
the research, Mr. Luke Blackwell and Dr. Sue Baigent for their contribution in the
animal studies, and Mr. Lawrence Petherbridge for his contribution in IBD virus
preparation. This work was supported by Defra (grant OD0722) and the
Biotechnology and Biological Sciences Research Council (grant BB/K002465/1).
AUTHOR CONTRIBUTIONS
Y.S. and V.N. designed the experiments. The experiments were performed by Y.S. The
manuscript was prepared by Y.S., S.S. and V.N. Animal experiments were performed
by Y.S., C.P., S.S., M.P. and A.B.
ADDITIONAL INFORMATION
Supplementary Information accompanies the paper on the npj Vaccines website
(https://doi.org/10.1038/s41541-018-0056-6).
Competing interests: The research project that led to this manuscript was funded
partly by the industry (Zoetis Inc.). The authors declare no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional affiliations.
REFERENCES
1. Witter, R. L. Protective efficacy of Marek’s disease vaccines. Curr. Top. Microbiol.
Immunol. 255, 57–90 (2001).
2. Calnek, B. W., Schat, K. A., Peckham, M. C. & Fabricant, J. Field trials with a bivalent
vaccine (HVT and SB-1) against Marek’s disease. Avian. Dis. 27, 844–849 (1983).
3. Morgan, R. W., Gelb, J. Jr, Pope, C. R. & Sondermeijer, P. J. Efficacy in chickens of a
herpesvirus of turkeys recombinant vaccine containing the fusion gene of
Newcastle disease virus: onset of protection and effect of maternal antibodies.
Avian Dis. 37, 1032–1040 (1993).
4. Li, Y. et al. Recombinant herpesvirus of turkeys as a vector-based vaccine against
highly pathogenic H7N1 avian influenza and Marek’s disease. Vaccine 29,
8257–8266 (2011).
5. Darteil, R. et al. Herpesvirus of turkey recombinant viruses expressing infectious
bursal disease virus (IBDV) VP2 immunogen induce protection against an IBDV
virulent challenge in chickens. Virology 211, 481–490 (1995).
6. Kapczynski, D. R. et al. Vaccine protection of chickens against antigenically
diverse H5 highly pathogenic avian influenza isolates with a live HVT vector
vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2
avian influenza virus. Vaccine 33, 1197–1205 (2015).
7. Li, K. et al. Protective efficacy of a novel recombinant Marek’s disease virus vector
vaccine against infectious bursal disease in chickens with or without maternal
antibodies. Vet. Immunol. Immunopathol. 186, 55–59 (2017).
8. American Association of Avian Pathologists (AAAP). Frequently asked questions
on viral tumor diseases. (2012) https://www.aaap.info/frequently-asked-
questions-on-viral-tumor-diseases.
9. Schat, K. A. & Calnek, B. W. Characterization of an apparently nononcogenic
Marek’s disease virus. J. Natl. Cancer Inst. 60, 1075–1082 (1978).
Gallid herpesvirus 3 SB-1 strain as a recombinant viral vector
Y Sadigh et al.
6
npj Vaccines (2018)  21 Published in partnership with the Sealy Center for Vaccine Development
10. Bublot, M. & Sharma, J. in Marek’s Disease—An Evolving Problem (eds Davison, F. &
Nair, V.) 168–185 (Elsevier Academic Press, 2004).
11. Witter, R. L. & Lee, L. F. Polyvalent Marek’s disease vaccines: safety, efficacy and
protective synergism in chickens with maternal antibodies. Avian Pathol. 13,
75–92 (1984).
12. Spatz, S. J. & Schat, K. A. Comparative genomic sequence analysis of the Marek’s
disease vaccine strain SB-1. Virus Genes. 42, 331–338 (2011).
13. Yao, Y. et al. Marek’s disease virus type 2 (MDV-2)-encoded microRNAs show no
sequence conservation with those encoded by MDV-1. J. Virol. 81, 7164–7170
(2007).
14. Petherbridge, L. et al. Cloning of Gallid herpesvirus 3 (Marek’s disease virus ser-
otype-2) genome as infectious bacterial artificial chromosomes for analysis of
viral gene functions. J. Virol. Methods 158, 11–17 (2009).
15. Singh, S. M., Baigent, S. J., Petherbridge, L. J., Smith, L. P. & Nair, V. K. Comparative
efficacy of BAC-derived recombinant SB-1 vaccine and the parent wild type strain
in preventing replication, shedding and disease induced by virulent Marek’s
disease virus. Res. Vet. Sci. 89, 140–145 (2010).
16. Zhao, Y. & Nair, V. in In Vitro Mutagenesis Protocols (ed Braman, J.) Ch. 4, 53–74
(Humana Press, 2010).
17. Fahey, K. J., Erny, K. & Crooks, J. A conformational immunogen on VP-2 of
infectious bursal disease virus that induces virus-neutralizing antibodies that
passively protect chickens. J. Gen. Virol. 70 (Pt 6), 1473–1481 (1989).
18. Lee, L. F., Liu, X. & Witter, R. L. Monoclonal antibodies with specificity for three
different serotypes of Marek’s disease viruses in chickens. J. Immunol. 130,
1003–1006 (1983).
19. Jackwood, D. J., Sreedevi, B., LeFever, L. J. & Sommer-Wagner, S. E. Studies on
naturally occurring infectious bursal disease viruses suggest that a single amino
acid substitution at position 253 in VP2 increases pathogenicity. Virology 377,
110–116 (2008).
20. Brown, M. D. & Skinner, M. A. Coding sequences of both genome segments of a
European ‘very virulent’ infectious bursal disease virus. Virus Res. 40, 1–15 (1996).
21. Schroder, A., van Loon, A. A., Goovaerts, D., Teifke, J. P. & Mundt, E. VP5 and the N
terminus of VP2 are not responsible for the different pathotype of serotype I and
II infectious bursal disease virus. J. Gen. Virol. 82, 159–169 (2001).
22. Tsukamoto, K. et al. Complete, long-lasting protection against lethal infectious
bursal disease virus challenge by a single vaccination with an avian herpesvirus
vector expressing VP2 antigens. J. Virol. 76, 5637–5645 (2002).
23. Perozo, F., Villegas, A. P., Fernandez, R., Cruz, J. & Pritchard, N. Efficacy of single
dose recombinant herpesvirus of turkey infectious bursal disease virus (IBDV)
vaccination against a variant IBDV strain. Avian. Dis. 53, 624–628 (2009).
24. Tsukamoto, K. et al. Protection of chickens against very virulent infectious bursal
disease virus (IBDV) and Marek’s disease virus (MDV) with a recombinant MDV
expressing IBDV VP2. Virology 257, 352–362 (1999).
25. Zhou, X. et al. Protection of chickens, with or without maternal antibodies,
against IBDV infection by a recombinant IBDV-VP2 protein. Vaccine 28,
3990–3996 (2010).
26. Muller, H., Mundt, E., Eterradossi, N. & Islam, M. R. Current status of vaccines
against infectious bursal disease. Avian Pathol. 41, 133–139 (2012).
27. Witter, R. L. Characteristics of Marek’s disease viruses isolated from vaccinated
commercial chicken flocks: association of viral pathotype with lymphoma fre-
quency. Avian. Dis. 27, 113–132 (1983).
28. Warming, S., Costantino, N., Court, D. L., Jenkins, N. A. & Copeland, N. G. Simple
and highly efficient BAC recombineering using galK selection. Nucleic Acids Res.
33, e36 (2005).
29. Mahgoub, H. Improved Vaccination Strategies for IBDV: Cytokines As Vaccine
Adjuvants. Doctoral thesis, University of Bristol (2010).
30. Eterradossi, N. et al. Pathogenicity and preliminary antigenic characterization of
six infectious bursal disease virus strains isolated in France from acute outbreaks.
Zent. Vet. B. 39, 683–691 (1992).
31. Brownie, C. et al. Estimating viral titres in solutions with low viral loads. Biologicals
39, 224–230 (2011).
32. Islam, A. et al. Differential amplification and quantitation of Marek’s disease
viruses using real-time polymerase chain reaction. J. Virol. Methods 119, 103–113
(2004).
33. Renz, K. G., Islam, A., Cheetham, B. F. & Walkden-Brown, S. W. Absolute quanti-
fication using real-time polymerase chain reaction of Marek’s disease virus ser-
otype 2 in field dust samples, feather tips and spleens. J. Virol. Methods 135,
186–191 (2006).
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in anymedium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
© The Author(s) 2018
Gallid herpesvirus 3 SB-1 strain as a recombinant viral vector
Y Sadigh et al.
7
Published in partnership with the Sealy Center for Vaccine Development npj Vaccines (2018)  21 
